Status:
COMPLETED
Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression
Lead Sponsor:
Tanta University
Collaborating Sponsors:
Mansoura University
Conditions:
Renal Insufficiency, Chronic
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
This randomized controlled trial aims at evaluating the efficacy and safety of the antidiabetics metformin versus empagliflozin on chronic kidney disease (CKD) progression in patients with CKD stages ...
Eligibility Criteria
Inclusion
- Patients with mild or/and moderate chronic kidney disease (stages 2 or/and 3, estimated glomerular filtration rate (eGFR) between 30-89 ml/min/1.73 m2) at the time of the baseline visit.
- Patients with and without type 2 diabetes.
- Patients with or without proteinuria.
- Age: ≥ 18 years.
Exclusion
- Type 1 diabetes.
- Patients with eGFR ˂30 ml/min/1.73 m2.
- Patients with known hepatic cell failure.
- Decompensated heart requiring acute management.
- Active malignancy.
- Planned coronary or surgical interventions.
- Known hypersensitivity to study medications.
- Chronic inflammation, trauma, or infection.
- Pregnant or lactating women.
- Patients already on metformin or a sodium-glucose cotransporter-2 (SGLT2) inhibitor.
- Any of the study treatments labeled contraindications.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2024
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT05373680
Start Date
January 1 2022
End Date
April 1 2024
Last Update
August 14 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura University
Al Mansurah, Dakahlia Governorate, Egypt
2
Tanta University Teaching Hospitals
Tanta, Gharbia Governorate, Egypt